Nomura downgraded Dr. Reddy’s (RDY) to Neutral from Buy with a INR 1,500 price target The firm thinks the Street is concerned about higher contribution from generic Revlimid that could start declining in fiscal 2026, saying Dr. Reddy’s overheads have increased significantly in the recent past. The company’s overhead spends remain high and revenues from new initiatives have not fully played out, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RDY:
- Dr. Reddy’s Subsidiary Faces Minor Penalty in Ukraine
- Dr. Reddy’s Laboratories to Host Investor Meeting
- Dr. Reddy’s Boosts Workforce with Equity Allotment
- Dr. Reddy’s Launches Innovative Cancer Drug in India
- Dr. Reddy’s Fined in Germany for Registration Lapse
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
